产超广谱β-内酰胺酶大肠埃希菌或肺炎克雷伯菌菌血症的碳青霉烯类治疗。
Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
机构信息
Department of Internal Medicine and Center for Infection Control, National Cheng Kung University Hospital and Medical College, Tainan, Taiwan.
出版信息
Diagn Microbiol Infect Dis. 2011 May;70(1):150-3. doi: 10.1016/j.diagmicrobio.2010.12.008. Epub 2011 Mar 12.
For 244 patients with bacteremia due to extended-spectrum β-lactamase (ESBL)-producing Escherichia coli or Klebsiella pneumoniae treated by ertapenem (73, 29.9%) or either imipenem or meropenem (171, 70.1%), the therapeutic efficacy was evaluated. Ertapenem therapy was effective for patients with ESBL-producing E. coli or K. pneumoniae bacteremia in terms of mortality and microbiological responses, as compared with imipenem or meropenem.
对于 244 例产超广谱β-内酰胺酶（ESBL）大肠埃希菌或肺炎克雷伯菌菌血症患者，分别接受厄他培南（73 例，29.9%）或亚胺培南或美罗培南（171 例，70.1%）治疗，评估了其治疗效果。与亚胺培南或美罗培南相比，厄他培南治疗产 ESBL 的大肠埃希菌或肺炎克雷伯菌菌血症患者在死亡率和微生物学应答方面有效。
Zotero 插件